

BMJ Open Bacterial meningitis in Finland, 1995–2014: a population-based observational study


This document has been downloaded from TamPub.uta.fi
The Institutional Repository of University of TampereAleksandra Polkowska,¹ Maija Toropainen,² Jukka Ollgren,² Outi Lyytikäinen,² J. Pekka Nuorti^{1,2}

To cite: Polkowska A, Toropainen M, Ollgren J, *et al.* Bacterial meningitis in Finland, 1995–2014: a population-based observational study. *BMJ Open* 2017;0:e015080. doi:10.1136/bmjopen-2016-015080

► Prepublication history and additional material are available. To view, please visit the journal (<http://dx.doi.org/10.1136/bmjopen-2016-015080>).

Received 9 November 2016
Revised 27 March 2017
Accepted 13 April 2017

ABSTRACT

Objectives Bacterial meningitis remains an important cause of morbidity and mortality worldwide. Its epidemiological characteristics, however, are changing due to new vaccines and secular trends. Conjugate vaccines against *Haemophilus influenzae* type b and *Streptococcus pneumoniae* (10-valent) were introduced in 1986 and 2010 in Finland. We assessed the disease burden and long-term trends of five common causes of bacterial meningitis in a population-based observational study.

Methods A case was defined as isolation of *S. pneumoniae*, *Neisseria meningitidis*, *Streptococcus agalactiae*, *Listeria monocytogenes* or *H. influenzae* from cerebrospinal fluid and reported to national, population-based laboratory surveillance system during 1995–2014. We evaluated changes in incidence rates (Poisson or negative binomial regression), case fatality proportions (χ^2) and age distribution of cases (Wilcoxon rank-sum).

Results During 1995–2014, *S. pneumoniae* and *N. meningitidis* accounted for 78% of the total 1361 reported bacterial meningitis cases. *H. influenzae* accounted for 4% of cases (92% of isolates were non-type b). During the study period, the overall rate of bacterial meningitis per 100 000 person-years decreased from 1.88 cases in 1995 to 0.70 cases in 2014 (4% annual decline (95% CI 3% to 5%). This was primarily due to a 9% annual reduction in rates of *N. meningitidis* (95% CI 7% to 10%) and 2% decrease in *S. pneumoniae* (95% CI 1% to 4%). The median age of cases increased from 31 years in 1995–2004 to 43 years in 2005–2014 ($p=0.0004$). Overall case fatality proportion (10%) did not change from 2004 to 2009 to 2010–2014.

Conclusions Substantial decreases in bacterial meningitis were associated with infant conjugate vaccination against pneumococcal meningitis and secular trend in meningococcal meningitis in the absence of vaccination programme. Ongoing epidemiological surveillance is needed to identify trends, evaluate serotype distribution, assess vaccine impact and develop future vaccination strategies.

INTRODUCTION

Despite the availability of vaccines, antibiotics and advances in intensive care, bacterial meningitis remains an important cause of morbidity and mortality worldwide. Persistent neurological sequelae including

Strengths and limitations of this study

- This study describes the epidemiological characteristics of >1300 cases of bacterial meningitis reported to national surveillance during 20 years in Finland.
- The study provides clinically important information on the changing distribution of pathogens and age of cases.
- The study documents the sustained population impact of infant conjugate vaccination against *Haemophilus influenzae* type b; and introduction of 10-valent pneumococcal conjugate vaccination on reducing the burden of bacterial meningitis, as well as decline in meningococcal meningitis due to secular trend. As the data were from laboratory-based surveillance system, clinical information such as severity or treatment was not available.
- Incidence rate of bacterial meningitis may be underestimated since cases diagnosed by PCR or antigen detection and culture-negative meningitis cases diagnosed based on clinical symptoms and findings were not included in the dataset.

hearing loss, neuropsychological impairment or seizures are reported in 10%–30% of survivors.¹ The case fatality proportion (CFP) ranges from 5% to 30% for different bacteria.^{2–3}

Globally, *Streptococcus pneumoniae*, *Neisseria meningitidis* and *Haemophilus influenzae* are the most important causes of bacterial meningitis, particularly in young children.^{4,5} Among neonates, the most common cause of bacterial meningitis is *S. agalactiae*,^{2,6} while *Listeria monocytogenes* is important in newborns and elderly persons with comorbidities.⁷ However, the leading organisms causing bacterial meningitis vary by age of the patient, time and geographical location.⁵ As the choice of empirical antimicrobial treatment for bacterial meningitis should be based on local epidemiology, patient's age, presence of risk factors and regional resistance patterns,^{8–10} population-based



¹School of Health Sciences, University of Tampere, Lääkärikatu, Tampere, Finland

²Department of Infectious Diseases, National Institute for Health and Welfare (THL), Mannerheimintie, Helsinki, Finland

Correspondence to

Prof. J. Pekka Nuorti;
pekka.nuorti@uta.fi

surveillance data are important to help in formulating clinical guidelines.

The introduction of effective protein conjugate vaccines against *H. influenzae* type b (Hib), *S. pneumoniae* and *N. meningitidis* has changed the epidemiology of bacterial meningitis in many countries.^{11 12} In Finland, universal vaccination against Hib since 1986 resulted in rapid elimination of the disease¹³ and introduction of the 10-valent pneumococcal conjugate vaccine (PCV10) in September 2010 has resulted in substantial reduction in vaccine-type invasive disease.^{14 15} Meningococcal conjugate vaccines (MCVs) have not been introduced into Finnish National Vaccination Programme (NVP). However, meningococcal polysaccharide vaccine has been offered to military conscripts since 1982.

To provide information for developing future prevention strategies and to help in formulating clinical guidelines, we conducted a population-based observational study to determine the contribution of specific pathogens to the total bacterial meningitis disease burden and to assess long-term trends in the incidence of common aetiologies in Finland during 1995–2014.

MATERIALS AND METHODS

Data sources

Since 1995, all clinical microbiology laboratories in Finland have had legal obligation to report microbial isolations from blood and/or cerebrospinal fluid (CSF) to the National Infectious Diseases Register (NIDR)—a population-based, electronic laboratory surveillance system maintained by the National Institute for Health and Welfare (THL). Routinely collected information include the microbe, specimen date, date of birth, sex, place of residence and unique Personal Identity Code (PIC). For blood or CSF findings concerning *S. pneumoniae*, *S. agalactiae*, *N. meningitidis*, *L. monocytogenes* or *H. influenzae*, multiple notifications with the same PIC and microbe are merged into one case if they occurred within 3 months of the first notification. Since 2004, information on vital status after episode is routinely obtained from the Population Information System. All clinical microbiology laboratories also submit isolates from reported cases to THL reference laboratories for species verification and characterisation of the isolates including serotyping or serogrouping. Since 2004, serotyping results are linked to NIDR notifications by using the PIC. Antimicrobial susceptibility data were not available.

Case definitions

We defined a case of bacterial meningitis as isolation of *S. pneumoniae*, *S. agalactiae*, *N. meningitidis*, *L. monocytogenes* or *H. influenzae* from CSF and notified to NIDR from 1995 through 2014.

For cases reported during 2004–2014, we calculated the pathogen-specific 30-day CFP as number of cases resulting in death within 30 days from the first positive CSF culture, divided by all cases.

We calculated the proportions of *S. pneumoniae*, *N. meningitidis* and *H. influenzae* cases due to vaccine-preventable serotypes/serogroups during 2004–2014. Serotypes covered in PCV10 are the following: 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F; the 13-valent PCV13 adds serotypes 3, 6A and 19A. Vaccine-preventable meningococcal serogroups include those in the quadrivalent MCV (MCV-4, A, C, W and Y) and serogroup B isolates targeted by novel protein-based vaccines (MenB). For *H. influenzae*, type b was considered vaccine preventable.

Statistical analysis

By using data from the Population Information System as denominators, we calculated pathogen-specific and age-specific annual incidence rates. Poisson regression was used to test for log-linear trend in rates of bacterial meningitis during 1995–2014. Incidence rate ratios (IRRs), their 95% CI and p values for yearly changes were calculated using time (year) as a continuous explanatory variable in the Poisson model. When appropriate, we used negative binomial regression to correct for overdispersion of data. To compare age distribution of cases across years, we used Wilcoxon rank-sum test. To assess changes in CFP, we used χ^2 analyses; p value <0.05 was considered statistically significant. All analyses were done with STATA version 13 and Microsoft Excel 2013.

Ethical considerations

Data used in the analysis were collected as a part of national routine surveillance which falls under the existing mandate of THL. No formal Institutional Review Board review was required for this study. Personal identifiers were removed after linkage with vital status data.

RESULTS

Overall incidence rates of bacterial meningitis

From 1995 to 2014, 1361 cases of bacterial meningitis caused by *S. pneumoniae*, *N. meningitidis*, *S. agalactiae*, *L. monocytogenes* or *H. influenzae* were reported (mean incidence rate, 1.29 cases/100 000 person-years, [table 1](#)). *S. pneumoniae* and *N. meningitidis* were the most common aetiologies accounting for 78% (1061/1361) of cases. The median age of cases increased from 31 years in 1995–2004 to 43 years in 2005–2014 (p=0.0004). Rates were higher in men than women (1.52 vs 1.07 cases/100 000 person-years; IRR 1.4, 95% CI 1.3 to 1.6)).

The mean annual rates of all bacterial meningitis ranged from 1.97 in 1996 to 0.70 cases/100 000 person-years in 2014, with an annual decrease of 4% (95% CI –3% to –5%, [table 1](#)). During 2004–2014, 65 patients died within 30 days from culture (CFP, 10% (65/633)). There was no change in 30-day CFP from 2004–2009 (11% (43/402) to 2010–2014 (10% (22/231), p=0.22).

Characteristic of bacterial meningitis by age group

Children <2 years of age accounted for 20% of cases (268/1361) and had the highest incidence rate (11.38 cases/100 000 person-years, [table 1](#)). The most common

Table 1 Number of cases (n), incidence rates per 100 000 person-years (IR) and mean annual relative change in incidence of bacterial meningitis, according to age group (years), Finland, 1995–2014

1995–1999			2000–2004			2005–2009			2010–2014			1995–2014			1995–2014		
	n	IR	n	IR	n	IR	n	IR	n	IR	n	IR	n	IR	% change*	95% CI	
Streptococcus pneumoniae																	
<2	26	4.32	25	4.43	18	3.05	14	2.33	83	3.52					–4	–7 to 0	
2–4	6	0.63	3	0.35	6	0.69	3	0.33	18	0.50					–1	–8 to 7	
5–17	13	0.31	11	0.26	7	0.17	2	0.05	33	0.20					–7	–13 to 1	
18–49	59	0.50	54	0.48	35	0.32	30	0.27	178	0.40					–4	–6 to 1	
50–64	41	0.91	52	1.00	56	0.99	37	0.65	186	0.88					–2	–4 to 1	
≥65	25	0.67	23	0.57	39	0.89	26	0.51	113	0.66					–1	–4 to 2	
All age groups	170	0.55	168	0.65	161	0.61	112	0.41	611	0.58					–2	–4 to 1	
Neisseria meningitidis																	
<2	23	3.83	23	4.07	8	1.36	14	2.33	68	2.89					–4	–8 to 0	
2–4	19	1.98	11	1.27	12	1.38	6	0.66	48	1.33					–6	–10 to –1	
5–17	37	0.88	16	0.38	24	0.60	7	0.18	84	0.52					–8	–14 to –3	
18–49	93	0.79	46	0.41	42	0.38	14	0.13	195	0.43					–10	–13 to –8	
50–64	15	0.33	15	0.29	7	0.12	2	0.04	39	0.18					–12	–17 to –6	
≥65	6	0.16	3	0.07	4	0.09	3	0.06	16	0.09					–7	–14 to 2	
All age groups	193	0.62	114	0.44	97	0.37	46	0.17	450	0.43					–9	–10 to –7	
Haemophilus influenzae																	
<2	4	0.67	3	0.53	2	0.34	1	0.17	10	0.42					–7	–17 to 4	
2–4	0	0.00	3	0.35	0	0.00	0	0.00	3	0.08					NA	NA	
5–17	5	0.12	4	0.10	0	0.00	2	0.05	11	0.07					–8	–17 to 3	
18–49	4	0.03	2	0.02	2	0.02	6	0.05	14	0.03					5	–5 to 15	
50–64	3	0.07	3	0.06	2	0.04	2	0.04	10	0.05					–3	–13 to 8	
≥65	2	0.05	0	0.00	7	0.16	1	0.02	10	0.06					1	–9 to 12	
All age groups	18	0.06	15	0.06	13	0.05	12	0.04	58	0.06					–2	–7 to 2	
S. agalactiae																	
<2	25	4.16	24	4.25	32	5.43	25	4.16	106	4.50					0	–3 to 5	
2–4	1	0.10	0	0.00	0	0.00	0	0.00	1	0.03					NA	NA	
5–17	0	0.00	1	0.02	0	0.00	0	0.00	1	0.01					NA	NA	

Continued

Table 1 Continued

1995–1999		2000–2004		2005–2009		2010–2014		1995–2014		1995–2014	
n	IR	n	IR	n	IR	n	IR	n	IR	% change*	95% CI
18–49	2	0.02	1	0.01	1	0.01	2	0.02	6	0.01	1 –12 to 16
50–64	4	0.09	2	0.04	7	0.12	3	0.05	16	0.08	1 –9 to 8
≥65	0	0.00	7	0.17	1	0.02	3	0.06	11	0.06	–2 –11 to 9
All age groups	32	0.10	35	0.13	41	0.15	33	0.12	141	0.13	0 –3 to 3
<i>Listeria monocytogenes</i>											
<2	1	0.17	0	0.00	0	0.00	0	0.00	1	0.04	NA NA
2–4	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	NA NA
5–17	1	0.02	0	0.00	0	0.00	0	0.00	1	0.01	NA NA
18–49	9	0.08	3	0.03	0	0.00	3	0.03	15	0.03	–11 –19 to –3
50–64	10	0.22	3	0.06	6	0.11	4	0.07	23	0.11	–6 –13 to 1
≥65	14	0.37	13	0.32	13	0.30	21	0.42	61	0.35	0 –4 to 4
All age groups	35	0.11	19	0.07	19	0.07	28	0.10	101	0.10	–2 –5 to 1
Total bacterial meningitis											
<2	79	13.14	75	13.28	60	10.18	54	8.99	268	11.38	–2 –4 to 1
2–4	26	2.71	17	1.97	18	2.07	9	0.98	70	1.94	–5 –10 to 0
5–17	56	1.33	32	0.77	31	0.77	11	0.28	130	0.80	–8 –12 to –4
18–49	167	1.43	106	0.94	80	0.73	55	0.50	408	0.91	–7 –8 to –5
50–64	73	1.63	75	1.44	78	1.37	48	0.84	274	1.30	–4 –6 to –2
≥65	47	1.25	46	1.15	64	1.46	54	1.07	211	1.23	–1 –4 to 1
All age groups	448	1.45	351	1.35	331	1.25	231	0.85	1361	1.29	–4 –3 to –5

*Mean annual relative change in incidence calculated by Poisson regression or negative binomial regression.
NA, not applicable.




Figure 1 Proportions of bacterial meningitis cases caused by five pathogens according to age group, Finland, 1995–2014.

pathogens in this age group were *S. agalactiae* (4.50 cases/100 000 person-years) and *S. pneumoniae* (3.52 cases/100 000 person-years, [figure 1](#)). From 1995 to 2014, the rate of bacterial meningitis in this age group decreased by 2% annually (95% CI –4% to –1%, [table 1](#)). The average 30-day CFP in 2004–2014 was 2% (3/140). In children 2–4 years of age, 70 cases (5%) of bacterial meningitis were reported during 1995 to 2014 (1.94 cases/100 000 person-years). The most common pathogens in this age group were *N. meningitidis* (1.33 cases/100 000 person-years) and *S. pneumoniae* (0.50 cases/100 000 person-years, [table 1](#)). During the study period, the rate of all meningitis did not change significantly ([table 1](#)). The 30-day CFP in 2004–2014 was 14% (4/28); all four deaths were due to *N. meningitidis*.

Children 5–17 years of age accounted for 130 cases (9%) of bacterial meningitis and had the lowest rate (0.80 cases/100 000 person-years, [table 1](#)). *N. meningitidis* and *S. pneumoniae* were the main causes (0.52 and 0.20 cases/100 000 person-years, respectively, [figure 1](#)). From 1995 to 2014, the rate of bacterial meningitis decreased by 8% annually (95% CI –12% to –4%, [table 1](#)). The 30-day CFP was 7% (3/45); all three fatal cases were due to *N. meningitidis*.

Adults 18–49 years of age accounted for 408 cases (30%) of bacterial meningitis (0.91 cases/100 000 person-years, [table 1](#)). *N. meningitidis* and *S. pneumoniae* caused most of the cases ([figure 1](#)), with incidence rates 0.43 and 0.40 cases/100 000 person-years, respectively. During 1995–2014, the overall rate decreased by 7% annually (95% CI –8% to –5%, [table 1](#)). The 30-day CFP was 8% (13/152), with nine deaths due to *S. pneumoniae* infection.

Among persons 50–64 years of age, there were 274 cases (20%) of bacterial meningitis (1.30 cases/100 000 person-years, [table 1](#)), of which 186 cases (68%) were caused by *S. pneumoniae* (0.88 cases/100 000 person-years, [figure 1](#)). During the study period, the overall rate decreased by 4% annually (95% CI –6% to –2%, [table 1](#)). The 30-day CFP was 13% (18/143), with most fatal cases attributable to *S. pneumoniae* (16 deaths).

In adults ≥65 years of age, there were 211 cases (15%) of bacterial meningitis (1.23 cases/100 000 person-years, [table 1](#)). *S. pneumoniae* caused 53% (113/211) of

the cases (0.66 cases/100 000 person-years), followed by *L. monocytogenes*. There was no significant change in the overall rate during 1995–2014 ([table 1](#)). This age group had the highest 30-day CFP (19%, 24/125). Half of the fatal cases were due to *S. pneumoniae* (12 deaths); *L. monocytogenes* caused 10 deaths.

Causes of bacterial meningitis

Streptococcus pneumoniae

From 1995 to 2014, 611 cases of pneumococcal meningitis were reported. Median age was 48 years; 57% of cases were male (male to female IRR, 1.4 95% CI 1.2 to 1.6, [table 2](#)). The overall annual rate per 100 000 person-years decreased from 0.70 in 1995 to 0.26 in 2014 ([figure 2](#)), a 2% annual decrease (95% CI –4% to –1%, [table 1](#)).

The incidence of pneumococcal meningitis decreased annually by 4% (95% CI –7% to 0%), 7% (95% CI –13% to –1%) and 4% (95% CI –6% to –1%) in age groups <2 years, 5–17 years and 18–49 years, respectively. During 2004–2014, *S. pneumoniae* accounted for 58% (38/65) of fatal cases (30-day CFP 12%, 38/308).

Of the 308 pneumococcal meningitis cases reported during 2004–2014, information on serotype was available for 296 (96%). The proportion of cases caused by PCV10 serotypes decreased from 61% (35/57) in 2004–2005 to 15% (9/36) in 2013–2014. PCV13 serotypes accounted for 70% (40/57) cases in 2004–2005 and 44% (16/36) in 2013–2014. In children less than 2 years, proportion of meningitis cases caused by PCV10 serotypes decreased from 75% (9/12) in 2004–2005 to 20% (1/5) in 2013–2014. In 2014, no meningitis cases were caused by PCV10 serotypes.

Neisseria meningitidis

During the study period, meningococcal meningitis accounted for 450 cases (0.43 cases/100 000 person-years) ([table 1](#)). Median age was 18 years and 60% of cases were male (male to female IRR 1.5, 95% CI 1.3 to 1.9, [table 2](#)). The overall annual incidence per 100 000 person-years decreased from 0.88 in 1995 to 0.07 in 2014; the annual decrease was –9% (95% CI –7% to –10%, [table 1](#)). The decline occurred in all age-groups except in <2 years

Table 2 Characteristics of bacterial meningitis cases, Finland, 1995–2014

Characteristics	<i>S. pneumoniae</i>	<i>N. meningitidis</i>	<i>S. agalactiae</i>	<i>L. monocytogenes</i>	<i>H. influenzae</i>	Total
Gender, no of cases (% of total)						
Male	347 (57)	268 (60)	70 (50)	71 (70)	28 (48)	784 (58)
Female	264 (43)	182 (40)	71 (50)	30 (30)	30 (52)	577 (42)
Age (years)						
Median	48	18	0	68	29	36
IQR	28–62	4–35	0	56–74	6–54	5–58
Case fatality*						
No of deaths (no of cases)	38 (308)	14 (163)	2 (86)	11 (50)	0 (26)	65 (633)
Case fatality proportion (%)	12.3	8.6	2.3	22	0	10.3

*Data are for cases reported during 2004–2014.

and ≥ 65 years of age. The incidence decreased annually by 6% (95% CI –1% to –10%), 8% (95% CI –3% to –14%), 10% (95% CI –8% to –13%) and 12% (95% CI –8% to –13%) in age groups 2–4 years, 5–17 years, 18–49 years and 50–64 years, respectively. The overall 30-day CFP was 9% (14/163) and ranged from 3% (1/29) among children aged 0–1 years to 21% (4/19) among children aged 2–4 years.

During 2004–2014, information on *N. meningitidis* serogroups was available for 99% of cases (161/163). Serogroup B accounted for 85% (137/161) of isolates, C 11% (17/161) and Y 4% (7/161). In children <2 years, serogroup B caused 96% (26/27) of cases. MCV-4 and MenB vaccine serogroups caused 15% (24/161) and 85% (137/161) of all cases, respectively.


Haemophilus influenzae

From 1995 to 2014, 58 cases of *H. influenzae* were reported (0.06 cases/100 000 person-years, table 1). Median age was 29 years and male to female IRR was 1.0 (95% CI 0.6 to 1.7, table 2). The incidence rate ranged from 0.0 cases per 100 000 person-years in 2010 to 0.25 cases in 2007 (figure 2). Rates in all age groups were stable. From 2004 to 2014, there were no deaths due to *H. influenzae*.

In 2004–2014, non-encapsulated *H. influenzae* accounted for 69% (18/26), serotype f 23% (6/26) and type b 8% (2/26) of isolates.

Streptococcus agalactiae

Infection with *S. agalactiae* accounted for 141 cases of meningitis (0.13 cases/100 000 person-years), including 24 early-onset cases and 78 late-onset cases (table 1). The median age of cases was 30 days; male to female IRR was 1.03 (95% CI 0.7 to 1.4) (table 2). During the study

**Figure 2** Incidence rate (per 100 000 person-years) of bacterial meningitis by year and pathogen, Finland, 1995–2014.

period, annual rates ranged from 0.06 cases/100 000 person-years in 1995 to 0.17 cases in 2014 (figure 2), but overall rates of *S. agalactiae* did not change significantly ($p=0.97$, table 1). During 2004–2014, the 30-day CFP was 2% (2/86).

Listeria monocytogenes

During the study period, *L. monocytogenes* caused 101 cases of meningitis (0.13 cases/100 000 person-years), mostly among elderly persons (median age, 68 years). Of cases, 70% were men (male to female IRR 2.5, 95% CI 1.6 to 3.9, table 2). Overall incidence rates of *Listeria* meningitis did not vary significantly during the study period, ranging from 0.04 to 0.21/100 000 person-years (table 1). The overall 30-day CFP was 22% (11/50) and 28% (10/36) in persons ≥ 65 years of age.

DISCUSSION

During 1995–2014, the most common causes of bacterial meningitis in Finland were *S. pneumoniae* and *N. meningitidis*. However, contribution of specific pathogens to the disease burden varied substantially by age. As in other developed countries, *S. agalactiae* was the most common cause of bacterial meningitis in children <1 years of age.⁶ The mean age of cases increased significantly during the study period mainly because of the decrease in incidence in children associated with PCV10 programme and declining secular trend in meningococcal meningitis.

During the study period, significant declines were seen in overall incidence of bacterial meningitis—primarily due to decreases in rates of *N. meningitidis* and *S. pneumoniae*. Of interest, the decrease in incidence of *N. meningitidis* was greater than for pneumococcal meningitis, although there is no routine vaccination programme for meningococcal disease in Finland. Changes in rates of meningococcal disease have also been observed in other countries in Europe and worldwide.^{16 17} The reasons for these declines in incidence are not clear but may be related to population immunity to circulating strains, changes in colonising organisms in the nasopharynx or increasing use of influenza vaccine. Also, changes in behavioural risk factors such as lower prevalence of smoking or crowding might contribute.^{18 19} In some countries, decreases were related to meningococcal vaccination. After the introduction of conjugate serogroup C meningococcal vaccine, vaccine serogroup disease nearly disappeared in England²⁰ and the Netherlands.²¹ Direct and indirect (herd protection) vaccine effects were also reported from other European countries including Spain, Ireland and Belgium.^{22 23} Immunisation of high risk groups with recently licensed protein-based vaccines targeted against meningococcal serogroup B might also be considered in Finland. However, updated cost-effective analysis is needed for decision-making about introduction of meningococcal vaccination programs.

Before the introduction of PCV10, considerable variation in pneumococcal meningitis incidence rates was

seen. As there were no major changes in surveillance or diagnostic practices in Finland, these changes may be related to emergence of new serotypes, selective pressure from antibiotic use or natural fluctuation in serotypes.^{24–26} The decline in pneumococcal meningitis incidence in children <2 years of age was associated with introduction of PCV10 in the NVP in 2010¹⁵; PCV10 serotypes in this age group were significantly reduced and by 2014 no vaccine serotype meningitis cases were reported. In vaccine-eligible children, the overall rate of pneumococcal meningitis was reduced by 46% as a result of a 69% reduction in PCV10-type meningitis.¹⁵ Many studies in USA and Europe have also documented significant declines in the incidence of pneumococcal meningitis in both vaccinated and unvaccinated groups after introduction of PCV programmes.^{11 12 27–29} In Finland, it might be possible to achieve further reductions with higher valency conjugate vaccine formulations.

The incidence rate of *L. monocytogenes*, *N. meningitidis* and *S. pneumoniae* was higher in men than women. *L. monocytogenes* meningitis cases were 2.5 times more likely to be men. Higher rates of listeriosis in males have also been observed in other studies.⁷ However, the reasons are unknown, but may be related to higher prevalence of underlying conditions, alcoholism among men and liver diseases (including alcoholic cirrhosis).³⁰ In pneumococcal and meningococcal meningitis, possible reasons may be higher prevalence of underlying medical conditions, smoking and alcoholism.³¹ As listeriosis is primarily transmitted through contaminated food, important prevention efforts include health education about dietary guidelines for high risk groups, such as pregnant women and the elderly.³²

The overall 30-day CFP for meningitis did not change significantly during 1995–2014. However, the unchanged CFP may be related to the altered age distribution of cases. Older age is associated with higher risk of poor outcome.³³ In addition, pathogen distribution has changed and the case fatality for meningococcal meningitis is lower compared with pneumococcal meningitis. The small number of fatal cases in our study did not allow assessing changes in CFP by age group and pathogen. The 30-day CFP was highest for *L. monocytogenes* (22%), which is comparable with results from the Netherlands and Spain.^{7 34} Most of the fatal cases of bacterial meningitis in persons ≥ 50 years were attributable to *S. pneumoniae*. Cases who had pneumococcal meningitis were older than those who were infected with other encapsulated bacteria and likely had higher prevalence of comorbidities increasing the risk of pneumococcal infection and poor outcome.³⁵ Because of lack of clinical data, we could not assess the potential impact of treatment changes, such as dexamethasone use, on case fatality. The relatively high CFP emphasises the importance of immediate initiation of treatment and supportive care after diagnosis to improve outcome of bacterial meningitis.

As expected, *H. influenzae* was the least common cause of bacterial meningitis. However, the stable number of cases

over 20 years suggest existence of small group of individuals with risk factors for *H. influenzae* (such as chronic respiratory disease and impaired immunity).³⁶ Conjugate vaccination has nearly eliminated Hib meningitis in many high-income countries.^{37 38} However, changes in the epidemiology of invasive *H. influenzae* have been observed and currently most cases occur in adults³⁹ and non-encapsulated, non-typable *H. influenzae* have dominated since 2004.

Because the data on laboratory confirmed cases are transmitted electronically directly from the clinical microbiology laboratories' database to the national surveillance database, a strength of our study is comprehensive case ascertainment. In addition, almost all isolates of *N. meningitidis*, *H. influenzae* and *S. pneumoniae* (98%) were available for serotyping/grouping at THL reference laboratory. However, our study has several limitations. As the data were from laboratory-based surveillance system, information on clinical presentation or treatment was not available. Therefore, culture-negative meningitis cases diagnosed on the basis of clinical symptoms and findings were not included in the analysis dataset. In addition, cases diagnosed by PCR or antigen detection were not included. As CSF cultures are negative in 11%–30% of patients with bacterial meningitis,⁴⁰ the total number of meningitis cases is underestimated. Another limitation is that NIDR database does not include information on the cause of death. However, most of deaths associated with bacterial meningitis occur early (within 14 days of admission), suggesting that they were related to the infection.⁴¹

In conclusion, this study describes the epidemiological characteristics of >1300 cases of bacterial meningitis reported to national surveillance over 20 years. It documents the sustained population impact of infant conjugate vaccination against Hib and introduction of PCV on reducing burden of bacterial meningitis as well as decline in meningococcal meningitis due to secular trend. However, disease burden had shifted to older people and no changes in the overall proportion of fatal cases were seen. Data on changes in causative organisms and age distribution for meningitis cases are important for evaluating clinical guidelines for empirical antibiotic therapy in bacterial meningitis. Continued epidemiological surveillance is necessary to monitor changing trends and serotype distribution, assessing the impact of vaccination programs and developing future vaccination strategies.

Contributors Study concept and design: AP, OL, PN. Acquisition of data: MT, JO, OL, PN. Analysis and interpretation of data: AP, MT, JO, OL, PN. Drafting of the manuscript: AP, PN. Critical revision of the manuscript for important intellectual content: AP, MT, JO, OL, PN. Statistical analysis: AP, JO. Obtained funding: PN. Study supervision: PN. Final approval: AP, MT, JO, OL, PN.

Funding This study was supported by the School of Health Sciences, University of Tampere and the National Institute for Health and Welfare (THL) in Helsinki, Finland.

Competing interests None declared.

Ethics approval Data used in the analysis were collected as a part of surveillance and infection control activities which falls under the existing mandate of the National Institute for Health and Welfare (THL).

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement No additional data are available.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES

- Edmond K, Clark A, Korczak VS, *et al*. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. *Lancet Infect Dis* 2010;10:317–28.
- Sáez-Llorens X, McCracken GH. Bacterial meningitis in children. *Lancet* 2003;361:2139–48.
- de Jonge RC, van Furth AM, Wassenaar M, *et al*. Predicting sequelae and death after bacterial meningitis in childhood: a systematic review of prognostic studies. *BMC Infect Dis* 2010;10:232.
- Brouwer MC, Tunkel AR, van de Beek D. Epidemiology, diagnosis, and antimicrobial treatment of acute bacterial meningitis. *Clin Microbiol Rev* 2010;23:467–92.
- Kim KS. Acute bacterial meningitis in infants and children. *Lancet Infect Dis* 2010;10:32–42.
- Le Doare K, Heath PT. An overview of global GBS epidemiology. *Vaccine* 2013;31 Suppl 4:D7–D12.
- Aouaj Y, Spanjaard L, van Leeuwen N, *et al*. *Listeria monocytogenes* meningitis: serotype distribution and patient characteristics in the Netherlands, 1976–95. *Epidemiol Infect* 2002;128:405–9.
- Nau R, Djukic M, Spreer A, *et al*. Bacterial meningitis: an update of new treatment options. *Expert Rev Anti Infect Ther* 2015;13:1401–23.
- van de Beek D, Brouwer MC, Thwaites GE, *et al*. Advances in treatment of bacterial meningitis. *Lancet* 2012;380:1693–702.
- Fitch MT, van de Beek D. Emergency diagnosis and treatment of adult meningitis. *Lancet Infect Dis* 2007;7:191–200.
- Dery MA, Hasbun R. Changing epidemiology of bacterial meningitis. *Curr Infect Dis Rep* 2007;9:301–7.
- McIntyre PB, O'Brien KL, Greenwood B, *et al*. Effect of vaccines on bacterial meningitis worldwide. *Lancet* 2012;380:1703–11.
- Peltola H, Kilpi T, Anttila M, *et al*. Rapid disappearance of *Haemophilus influenzae* type b meningitis after routine childhood immunisation with conjugate vaccines. *Lancet* 1992;340:592–4.
- Palmu AA, Jokinen J, Borys D, *et al*. Effectiveness of the ten-valent pneumococcal *Haemophilus influenzae* protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial. *Lancet* 2013;381:214–22.
- Jokinen J, Rinta-Kokko H, Siira L, *et al*. Impact of ten-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in Finnish children—a population-based study. *PLoS One* 2015;10:e0120290.
- European Centre for Disease Prevention and Control. Surveillance of invasive bacterial diseases in Europe, 2012. *Stockholm: ECDC* 2015.
- Cohn AC, MacNeil JR, Harrison LH, *et al*. Changes in *Neisseria meningitidis* disease epidemiology in the United States, 1998–2007: implications for prevention of meningococcal disease. *Clin Infect Dis* 2010;50:184–91.
- Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. *Vaccine* 2009;27(Suppl 2):B51–B63.
- Sadarangani M, Pollard AJ. Can we control all-cause meningococcal disease in Europe? *Clin Microbiol Infect* 2015;22:S103–12.
- Martin NG, Sadarangani M, Pollard AJ, *et al*. Hospital admission rates for meningitis and septicaemia caused by *Haemophilus influenzae*, *Neisseria meningitidis*, and *Streptococcus pneumoniae* in children in England over five decades: a population-based observational study. *Lancet Infect Dis* 2014;14:397–405.
- Bijlsma MW, Bekker V, Brouwer MC, *et al*. Epidemiology of invasive meningococcal disease in the Netherlands, 1960–2012: an analysis of national surveillance data. *Lancet Infect Dis* 2014;14:805–12.
- Trotter CL, Ramsay ME. Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines. *FEMS Microbiol Rev* 2007;31:101–7.
- Maiden MC, Ibarz-Pavón AB, Urwin R, *et al*. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. *J Infect Dis* 2008;197:737–43.



24. Klemets P, Lyytikäinen O, Ruutu P, *et al.* Trends and geographical variation in invasive pneumococcal infections in Finland. *Scand J Infect Dis* 2008;40:621–8.
25. Harboe ZB, Benfield TL, Valentiner-Branth P, *et al.* Temporal trends in invasive pneumococcal disease and pneumococcal serotypes over 7 decades. *Clin Infect Dis* 2010;50:329–37.
26. Black S. The Volatile Nature of Pneumococcal Serotype Epidemiology. *Pediatr Infect Dis J* 2009;1.
27. Vestrheim DF, Løvoll O, Aaberge IS, *et al.* Effectiveness of a 2+1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway. *Vaccine* 2008;26:3277–81.
28. Hsu HE, Shutt KA, Moore MR, *et al.* Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. *N Engl J Med* 2009;360:244–56.
29. Tsai CJ, Griffin MR, Nuorti JP, *et al.* Changing epidemiology of pneumococcal meningitis after the introduction of pneumococcal conjugate vaccine in the United States. *Clin Infect Dis* 2008;46:1664–72.
30. Liatsos GD, Thanellas S, Pirounaki M, *et al.* *Listeria monocytogenes* peritonitis: presentation, clinical features, treatment, and outcome. *Scand J Gastroenterol* 2012;47:1129–40.
31. Klemets P, Lyytikäinen O, Ruutu P, *et al.* Invasive pneumococcal infections among persons with and without underlying medical conditions: implications for prevention strategies. *BMC Infect Dis* 2008;8:96.
32. National Institute for Health and Welfare, THL, Helsinki, Finland. <https://www.thl.fi/en/web/infektioaudit/taudit-ja-mikrobit/bakteeritaudit/listeria>
33. Bodilsen J, Dalager-Pedersen M, Schønheyder HC, *et al.* Dexamethasone treatment and prognostic factors in community-acquired bacterial meningitis: a danish retrospective population-based cohort study. *Scand J Infect Dis* 2014;46:418–25.
34. Amaya-Villar R, García-Cabrera E, Sulleiro-Igual E, *et al.* Three-year multicenter surveillance of community-acquired *Listeria monocytogenes* meningitis in adults. *BMC Infect Dis* 2010;10:324.
35. Bijlsma MW, Brouwer MC, Kaskanmoentalib ES, *et al.* Community-acquired bacterial meningitis in adults in the Netherlands, 2006–14: a prospective cohort study. *Lancet Infect Dis* 2016;16:1–9.
36. Ladhani S, Slack MP, Heath PT, *et al.* Invasive *Haemophilus influenzae* disease, Europe, 1996–2006. *Emerg Infect Dis* 2010;16:455–63.
37. Peltola H. Worldwide *Haemophilus influenzae* type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. *Clin Microbiol Rev* 2000;13:302–17.
38. Watt JP, Wolfson LJ, O'Brien KL, *et al.* Burden of disease caused by *Haemophilus influenzae* type b in children younger than 5 years: global estimates. *Lancet* 2009;374:903–11.
39. Dworkin MS, Park L, Borchardt SM. The changing epidemiology of invasive *Haemophilus influenzae* disease, especially in persons > or = 65 years old. *Clin Infect Dis* 2007;44:810–6.
40. Brouwer MC, Van De Beek D, Heckenberg SG, *et al.* Meningitis in adults. *Clin Infect Dis* 2006;43:1233–8.
41. McMillan DA, Lin CY, Aronin SI, *et al.* Community-acquired bacterial meningitis in adults: categorization of causes and timing of death. *Clin Infect Dis* 2001;33:969–75.

BMJ Open

Bacterial meningitis in Finland, 1995–2014: a population-based observational study

Aleksandra Polkowska, Maija Toropainen, Jukka Ollgren, Outi Lyytikäinen and J. Pekka Nuorti

BMJ Open 2017 7:

doi: 10.1136/bmjopen-2016-015080

Updated information and services can be found at:

<http://bmjopen.bmj.com/content/7/5/e015080>

These include:

References

This article cites 38 articles, 2 of which you can access for free at:

<http://bmjopen.bmj.com/content/7/5/e015080#BIBL>

Open Access

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections

Articles on similar topics can be found in the following collections

[Epidemiology](#) (2101)

Notes

To request permissions go to:

<http://group.bmj.com/group/rights-licensing/permissions>

To order reprints go to:

<http://journals.bmj.com/cgi/reprintform>

To subscribe to BMJ go to:

<http://group.bmj.com/subscribe/>